Your session is about to expire
← Back to Search
Ceritinib for Non-Small Cell Lung Cancer
Study Summary
This trial compared the effectiveness of LDK378 to chemotherapy in patients who had already been treated with both chemotherapy and crizotinib.
- Non-Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 231 Patients • NCT01828112Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have already been treated with crizotinib for your advanced lung cancer.
- Group 1: Ceritinib
- Group 2: Chemotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many different medical facilities in this state are testing this new medication?
"This trial has 14 enrolling patients, including Cancer Specialists of North Florida in Jacksonville, Texas Oncology Cancer Care and Research Center in Waco, and Swedish Cancer Institute SC-1 in Seattle, as well as other sites."
What was the outcome of the FDA's review of ceritinib?
"Ceritinib is considered safe due to its Phase 3 status and supporting data, scoring a 3 on Power's safety scale."
Are there other existing studies that have used Ceritinib in the past?
"Presently, 557 clinical trials are underway to research Ceritinib. Of those active studies, 216 are in Phase 3. The majority of studies are based in Fuzhou, Fujian; however, there are 39014 locations running trials for this medication globally."
What are Ceritinib's most common indications?
"Ceritinib is an effective treatment for head, soft tissue sarcoma (sts), and metastatic ureter urothelial carcinoma."
Share this study with friends
Copy Link
Messenger